Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
04:05pm, Thursday, 25'th Apr 2024
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ad
Why Biogen Stock Leaped Nearly 5% Higher Today
06:18pm, Wednesday, 24'th Apr 2024
The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently
3-Stock Lunch: TXN, BIIB & CMG
05:05pm, Wednesday, 24'th Apr 2024
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
02:01pm, Wednesday, 24'th Apr 2024
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
11:25am, Wednesday, 24'th Apr 2024
Biogen Inc. (NASDAQ:BIIB ) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Of
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Wednesday, 24'th Apr 2024
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street e
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
08:51am, Wednesday, 24'th Apr 2024
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
Biogen Q1 2024 results surpass expectation despite revenue decline
07:45am, Wednesday, 24'th Apr 2024
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quar
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
06:48am, Wednesday, 24'th Apr 2024
Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition.
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
06:47am, Wednesday, 24'th Apr 2024
Alzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
What's in Store for Biogen (BIIB) This Earnings Season?
10:40am, Friday, 19'th Apr 2024
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
10:20am, Friday, 19'th Apr 2024
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know
06:56pm, Monday, 01'st Apr 2024
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
12:26pm, Tuesday, 26'th Mar 2024
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
07:29am, Friday, 22'nd Mar 2024
The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.
